首页> 外文期刊>Progress in Artificial Intelligence >Systematic review and meta-analysis protocol for efficacy and safety of Momordica charantia L. on animal models of type 2 diabetes mellitus
【24h】

Systematic review and meta-analysis protocol for efficacy and safety of Momordica charantia L. on animal models of type 2 diabetes mellitus

机译:系统综述和MOMORDIA Charantia L.疗效和安全性的荟萃分析方案。在2型糖尿病的动物模型上

获取原文
获取原文并翻译 | 示例
           

摘要

Background Studies on several preclinical models of type 2 diabetes mellitus have been conducted to establish the hypoglycemic activity of Momordica charantia L. Concerned with appropriateness of these models, we designed a systematic review to establish the efficacy and safety of M. charantia L. in preclinical models of type 2 diabetes mellitus. Methods Review authors will search without language restriction in MEDLINE/PubMed, Web of Science, Embase, Scopus, and CINAHL databases through April 2019. Search filters will be applied to enhance search efficiency. The authors will search for gray literature in Google and Google Scholar, OpenGrey, and ProQuest Dissertations & Theses. Two authors will evaluate full texts, extract data, and asses risk of bias independently. The review will include randomized or non-randomized studies that assessed the efficacy or safety of M. charantia L. with vehicle control group. The primary endpoint will be fasting blood glucose level. We will use Egger's test to assess publication biases. Chi-square test and I-2 will be used to assess heterogeneity in effect size of the primary outcome. Using RevMan software version 5.3, the authors will perform a meta-analysis of quantitative data. Discussion The strength of evidence will be rated as high, moderate, low, or very low using GRADE framework for animal studies. This systematic review will potentially improve research practice by identifying risks of bias and design features that compromise translatability and contribute to evidence-based clinical trial design. Systematic review registration PROSPERO CRD42019119181
机译:关于2型糖尿病的几种临床前模型的背景研究已经进行了,以确定Momordica Charantia L.关注这些模型的适当性的低血糖活性,我们设计了系统审查,以确定M. Charantia L.在临床前的疗效和安全性。 2型糖尿病的模型。方法查看作者将在2019年4月在Medline / Pubmed,Science,Scase,Scopus和Cinahl数据库中没有语言限制搜索。搜索过滤器将应用于提高搜索效率。作者将在Google和Google Scholar,OpenGrey和Proquest论文和论文中搜索灰色文学。两位作者将评估完整的文本,提取数据,并独立偏离偏差风险。审查将包括随机或非随机研究,评估M. Charantia L.与载体对照组的疗效或安全性。主要终点将是空腹血糖水平。我们将使用Egger的测试来评估出版物偏见。 Chi-Square测试和I-2将用于评估主要结果的效果大小的异质性。使用Revman Software 5.3版,作者将对定量数据进行META分析。讨论使用级别的动物研究框架,证据强度将被评为高,中等,低,低,或非常低。该系统审查将通过识别损害易性的偏见和设计特征的风险,潜在地改善研究实践,并有助于促进基于证据的临床试验设计。系统审查登记Prospero CRD42019119181

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号